White Paper

Navigating The Translation To Clinic: Future-Proof Your Plasmid Products

Source: Charles River
iStock-1293772874-lab-plasmid-gene therapy-DNA

The second installment in a three-part series exploring the challenges and considerations for cell and gene therapy development, from bench through commercial supply.

  • Early development – using the right material
  • Translation from development to clinic – reducing risk and timelines
  • Clinical to commercial – scalability and supply chain simplification

The successful outcome of pre-clinical studies on vectors generated from research grade (non-GMP) plasmids provides the basis for the progression into first-in-human studies, and therefore represents a critical milestone in the product’s development. It also represents a change in terms of the management of a project, the regulatory environment in which it is performed, and the people and skills required from both a client and plasmid supplier perspective.

Future-proofing products with strategies that reduce risk and timelines for later stages can be resource-intensive but add significant value. In this follow-on whitepaper we explore the challenges often encountered progressing from development to clinic.

Read Part 1 here.

access the White Paper!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.

Subscribe to Cell & Gene X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Cell & Gene